- A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP — Recruiting • Phase III • NCT07091630.
- A new drug (empasiprubart) is being tested to see if it safely improves symptoms in adults with chronic nerve inflammation (CIDP).
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emnergize Conditions: Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy Interventions: Empasiprubart IV, Placebo IV Lead Sponsor: argenx Planned Enrollment: 160 participants